Title: Biotransformation of Daclatasvir In Vitro and in Nonclinical Species: Formation of the Main Metabolite by Pyrrolidine δ-Oxidation and Rearrangement.
Journal: Drug metabolism and disposition: the biological fate of chemicals 20160601
Title: Daclatasvir: A NS5A Replication Complex Inhibitor for Hepatitis C Infection.
Journal: The Annals of pharmacotherapy 20160101
Title: Design, synthesis and evaluation of novel anti-HCV molecules that deliver intracellularly three highly potent NS5A inhibitors.
Journal: Bioorganic & medicinal chemistry letters 20150901
Title: Design and synthesis of imidazole N-H substituted amide prodrugs as inhibitors of hepatitis C virus replication.
Journal: Bioorganic & medicinal chemistry letters 20150815
Title: Daclatasvir-like inhibitors of NS5A block early biogenesis of hepatitis C virus-induced membranous replication factories, independent of RNA replication.
Journal: Gastroenterology 20141101
Title: Hepatitis C virus NS5A replication complex inhibitors: the discovery of daclatasvir.
Journal: Journal of medicinal chemistry 20140313
Title: Synthesis and evaluation of non-dimeric HCV NS5A inhibitors.
Journal: Bioorganic & medicinal chemistry letters 20130401
Title: Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life.
Journal: Proceedings of the National Academy of Sciences of the United States of America 20130305
Title: Combination treatment with hepatitis C virus protease and NS5A inhibitors is effective against recombinant genotype 1a, 2a, and 3a viruses.
Journal: Antimicrobial agents and chemotherapy 20130301
Title: Combinations of lambda interferon with direct-acting antiviral agents are highly efficient in suppressing hepatitis C virus replication.
Journal: Antimicrobial agents and chemotherapy 20130301
Title: HCV NS5A replication complex inhibitors. Part 3: discovery of potent analogs with distinct core topologies.
Journal: Bioorganic & medicinal chemistry letters 20130201
Title: Daclatasvir: potential role in hepatitis C.
Journal: Drug design, development and therapy 20130101
Title: HCV NS5A replication complex inhibitors. Part 2: investigation of stilbene prolinamides.
Journal: Bioorganic & medicinal chemistry letters 20121001
Title: Correlation between NS5A dimerization and hepatitis C virus replication.
Journal: The Journal of biological chemistry 20120831
Title: A sensitive and accurate liquid chromatography-tandem mass spectrometry method for quantitative determination of the novel hepatitis C NS5A inhibitor BMS-790052 (daclastasvir) in human plasma and urine.
Journal: Journal of chromatography. A 20120706
Title: In vitro activity of BMS-790052 on hepatitis C virus genotype 4 NS5A.
Journal: Antimicrobial agents and chemotherapy 20120301
Title: Treatment of chronic hepatitis C--are interferons really necessary?
Journal: Liver international : official journal of the International Association for the Study of the Liver 20120201
Title: Preliminary study of two antiviral agents for hepatitis C genotype 1.
Journal: The New England journal of medicine 20120119
Title: Small molecules targeting hepatitis C virus-encoded NS5A cause subcellular redistribution of their target: insights into compound modes of action.
Journal: Journal of virology 20110701
Title: Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system.
Journal: Antimicrobial agents and chemotherapy 20100901
Title: Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect.
Journal: Nature 20100506
Title: Min Gao, et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature. 2010 May 6;465(7294):96-100.
Title: David B Ascher, et al. Potent hepatitis C inhibitors bind directly to NS5A and reduce its affinity for RNA. Sci Rep. 2014 Apr 23;4:4765.
Title: Tomomi Furihata, et al. Different interaction profiles of direct-acting anti-hepatitis C virus agents with human organic anion transporting polypeptides. Antimicrob Agents Chemother. 2014 Aug;58(8):4555-64.
Title: Seung-Hoon Lee, et al. HA1077 displays synergistic activity with daclatasvir against hepatitis C virus and suppresses the emergence of NS5A resistance-associated substitutions in mice. Sci Rep. 2018 Aug 20;8(1):12469.
